MRI abnormalities are seen in 81% of cases due to anti-CTLA-4 treatment and in 18% of patients with a hypophysitis who were treated with anti-PD-1/anti-PD-L1, typically with an initial enlargement of the pituitary, which returns to normal within weeks (31). Here, CTLA4 is linked to hypophysitis.